Dow opens above 23,000, powered by IBM
October 18, 2017
IBM shares head for biggest gain in eight years
October 18, 2017

Allergan ruling casts doubt on tribal patent strategy

(Reuters) – A U.S. judge’s ruling on Monday invalidating Allergan Plc’s patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company’s novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.

Powered by WPeMatico